Evidence map›Paper›PMID 41789949›Full record

ArticleAmerican journal of epidemiology2026

Comparison of disease risk score methods to study treatment effect heterogeneity: a simulation study.

Haedi E Thelen, Wei Yang, Sean Hennessy, Jordana Cohen, Wensheng Guo, Todd A Miano

Abstract readComparative Study
In one paragraph

Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Haedi E ThelenDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-8357-2255
Wei YangDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0001-8984-4389
Sean HennessyDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-4726-9413
Jordana CohenDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0003-4649-079X
Wensheng GuoDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-8892-4309
Todd A MianoDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, United States.ORCID 0000-0002-3832-6212

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Clinical Pharmacoepidemiology Training ProgramT32GM075766 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Sean Hennessy, Charles Edward Leonard · 2006 to 2026
$8.4M
Dynamic Longitudinal Functional Models with Applications to the CRIC StudyR01HL161303 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DEO, RAJAT, GUO, WENSHENG · 2022 to 2025
$2.8M
Markers of Nephrotoxicity during treatment with Antibiotic Combinations: The MONACO clinical trialR01DK140714 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Todd Anthony Miano · 2025 to 2026
$1.6M
Drug-drug interactions and kidney disease in hospitalized patientsK08DK124658 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI MIANO, TODD ANTHONY · 2021 to 2025
$791k
Acute Kidney Injury with Immune Checkpoint Inhibitors and Beta-Lactam AntibioticsF32DK141217 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI THELEN, HAEDI · 2024 to 2024
$84k
NCATS NIH HHS UL1 TR001878NHLBI NIH HHS R01 HL161303NIDDK NIH HHS F32 DK141217NIDDK NIH HHS K08 DK124658NIDDK NIH HHS R01 DK140714NIGMS NIH HHS T32 GM075766NIH HHS 1F32DK141217NIH HHS 5T32GM075766NIH HHS K08DK124658NIH HHS R01DK140714NIH HHS R01HL161303NIH HHS UL1TR001878
6 · The paper itself

Abstract

Estimating treatment effects across disease risk scores (DRSs) is a common approach for assessing treatment effect heterogeneity in randomized trials. When external models are unavailable, the optimal approach for internally fitting the DRS model remains uncertain. This simulation study compares 3 internal derivation approaches, evaluating bias of estimated treatment effects within DRS-defined strata. We simulated trials under varying treatment effects (odds ratios [OR] of 1, 0.8, and 0.5) and treatment-covariate interactions. We fit DRS models on (1) a controls-only method, (2) the full sample ignoring treatment assignment, and (3) a random split-sample method of 50% of the controls, who were removed from the second stage of analysis. Additional simulations varied outcome incidence, sample size, randomization ratio, and the true DRS C-statistic. Bias decreased with the split-sample method (overall percent bias [OPB] 7.7% for OR = 0.8 with interactions) compared to the controls-only (OPB = 15.6%) and full-sample methods (OPB = 22.1%). Bias decreased more with the split-sample method than with controls-only and full-sample methods with larger sample sizes, higher outcome incidence, greater treated-to-control ratios, and larger C-statistics. These findings suggest split-sample methods may be the preferred approach to estimate treatment effect heterogeneity by the DRS in trials with sufficient data to support stable prediction modeling.

Indexed as

Models, StatisticalRandomized Controlled Trials as TopicTreatment Effect HeterogeneityBiasComputer SimulationHumansRisk AssessmentSample Sizeclinical prediction modelsclinical trialeffect modificationrisk predictiontreatment effect heterogeneity

Identifiers

PMID41789949
PMCPMC13343381

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.